Takeda Raises 2024 Outlook: Now Expects Revenue Of ¥4.48T (Prior ¥4.35T) Vs. ¥4.497T Est.; And Core EPS Of ¥456 (Prior ¥431); Sees Adjusted Free Cash Flow Of ¥400B-¥500B (Prior ¥350B - ¥450B)

Takeda Pharmaceutical Company Limited +0.07% Post

Takeda Pharmaceutical Company Limited

TAK

13.57

13.57

+0.07%

0.00% Post

Updating Full Year Management Guidance, and Reported and Core Forecasts

Takeda's FY2024 Management Guidance has been upgraded, primarily due to milder than anticipated generic erosion of VYVANSE and strong business momentum. Furthermore, also reflecting expected foreign exchange rates during the remaining second half of FY2024, Takeda's FY2024 reported and Core forecasts have been revised from the original forecast.

FY2024 Management Guidance Core Change at CER (Non-IFRS)
  FY2024 ORIGINAL MANAGEMENT GUIDANCE

(May 2024)
FY2024 REVISED MANAGEMENT GUIDANCE

(October 2024)
Core Revenue Flat to slightly declining Flat to slightly increasing
Core Operating Profit Approximately 10% decline Mid-single-digit % decline
Core EPS (Yen) Mid-10s% decline Approx 10% decline
FY2024 Reported and Core Forecasts

(Billion yen, except percentages and per share amounts)
 

FY2024

ORIGINAL FORECAST

(May 2024)

FY2024

REVISED FORECAST

(October 2024)

Revenue 4,350.0 4,480.0
Core Revenue (Non-IFRS) 4,350.0 4,480.0
Operating Profit 225.0 265.0
Core Operating Profit (Non-IFRS) 1,000.0 1,050.0
Net Profit 58.0 68.0
EPS (Yen) 37 43
Core EPS (Yen) (Non-IFRS) 431 456
Adjusted Free Cash Flow (Non-IFRS) 350.0 - 450.0 400.0-500.0
Annual Dividend per Share (Yen) 196 196
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via